analyze such findings including the types of treated diseases, the indications and dosage of each applied drug to establish more effective and safer antihypertensive pharmacotherapies .
The purpose of antihypertensive therapy is not only to normalize the blood pressure but also to prevent severe or fatal complications of the cardiovascular system. Since the presence or absence of target organ failure and major dangerous factors influence the prognosis of hypertension, an appropriate evaluation of these risk factors is important. It is therefore necessary to consider such complications when evaluating antihypertensive therapy.
In this investigation, we examined the current state regarding the use of antihypertensive drugs and their associated complications in Takarazuka City Hospital, to establish a more effective and safer pharmacotherapy from the pharmacist's viewpoint.
A total of 312 patients (138 males, 174 females) who received antihypertensive drugs at the Department of Internal Medicine in our hospital between August 23rd and 27th, 1999 were included in this study. The patients' records were examined with regard to age, the medication received and the complications observed . The rates of congestive heart failure (CHF) and ischemic heart disease (IHD) tended to increase with age . On the other hand, those of endocrine metabolic diseases such as diabetes mellitus (DM), hyperlipidemia and gout were either unaffected or tended to decrease with age. 
Introduction
In recent years, treatments based on the concept of " evidence-based medicine" has been proposed, and the introduction of guidelines (GL) for various diseases has been suggested for clinical use1). In 1990, the Ministry of Health and Welfare and the Japan Medical Association published the "Guidelines for vetting of hypertension"2), but it has not subsequently been revised. Therefore, GL which incorporate the new concept are desirable. On the other hand, GL are determined in the Japanese Society of Hypertension, while in the rest of the world the reports of the World Health Organization/International Society of Hypertension (WHO/ISH) and Joint National Committee (JNC) are widely used. In these GL, standard treatment procedures and appropriate medications are determined based on the presence or absence of cardiovascular risk factors and complications3,4). Therefore, it is necessary to consider such complications when evaluating antihypertensive therapy.
Previously, there have been a number of reports concerning the use of various antihypertensive drugs, but few studies have analyzed their use with regard to associated complications5). Moreover, few reports recognize the spread of GL to general hospitals such as ours.
In this study, we analyzed the current state regarding the use of antihypertensive drugs and their associated complications in Takarazuka City Hospital, to establish more effective and safer pharmacotherapy from the pharmacist's viewpoint.
Methods

Patients
A total of 312 patients (138 males, 174 females) who received antihypertensive drugs at the Department of Internal Medicine, Takarazuka City Hospital between August 23rd and 27th, 1999 were included in this study. Patients were separated into groups depending on age; "give age groups". The patients' case records were examined with regard to age, the medication received and the complication observed. Diagnosis was confirmed based on a review of their records. The diagnostic names of complications were from insurance diagnostic procedures. Data from cases showing more than one complication were processed along with those of each applicable disease group. And it examined the diseases which showed more than 5% of all the cases. 
Results
In this study, 357 patients were initially included, but 45 were excluded as the review of their case records did not indicate a diagnosis of "hypertension".
Therefore, the study population included a total of 312 patients. The patient characteristics are shown in Table 1 .
Rates of prescription of several antihypertensive drugs divided according to age are shown in Fig. 1 . With the exception of the 20-39 age group, the most commonly prescribed antihypertensive drugs were Ca channel blockers (Ca blockers), followed by angiotensin converting enzyme inhibitors (ACE-I). In the case of a -adrenergic blockers ( a blockers), its rate of use was higher in the younger age groups.
The rates of various complications in each age group are shown in Fig. 2 . The rates of congestive heart failure (CHF) and ischemic heart disease (IHD) tended to increase with age. On the other hand, those of endocrine metabolic diseases such as diabetes mellitus (DM), hyperlipidemia and 
Discussion
The purpose of antihypertensive therapy is not only to normalize the blood pressure but also to prevent severe or fatal complications of the cardiovascular system. Also, the presence or absence of target organ failure and major dangerous factors influence the prognosis of hypertension. Therefore, an appropriate evaluation of these risk factors is important. The WHO/ISH GL and JNC VI outlined standard treatment procedures on the presence or absence of coronary vascular risk and complications, and indicated appropriate antihypertensive treatment regimens based on these parameters3,4). It is necessary to consider such complications when evaluating antihypertensive therapy. In this study, we examined the current state regarding the use of antihypertensive drugs and their associated complications from the pharmacist's viewpoint.
Firstly, we investigated the prescription rates of various antihypertensive drugs according to patient's age. With the exception of the 20-39 age group, in which the number of patients was small, the most commonly prescribed antihypertensive drugs were Ca blockers. Ca blockers were reported to be used in more than 70% of cases at large special facilities (e.g. the National Cardiovascular Center, Japan)6). Our results were in agreement with this previous report. The specific hypotensive actions of these drugs facilitate their use. Also, severe side effects or internal organ dysfunction such as renal failure were seldom reported, making it comparatively simple to determine appropriate dosage regimens for large numbers of patients7). However, these agents were reported to cause recurrence and mortality of myocardial infarction to increase in hypertensive subjects8) or subjects with coronary artery diseases9). There is some degree of controversy regarding their use. It is, therefore, necessary to perform further large scale clinical trials to reevaluate the position of Ca blockers.
The next most prescribed drugs were ACE-I. These have mild effects, various organ protective actions and few severe side effects'). Therefore, they are widely used as the first choice of antihypertensive therapy in Japan. On the other hand, ACE-I has sometimes seen restricted use in patients with renal failure. Renal function generally declines with age, which may have been responsible for the observed tendency for its use to decrease in older subjects. But, in this study, we were unable to discuss this relationship in detail, because of the lack of considerations to its function. Only one patient was treated with angiotensin-II (AT-II ) antagonists during this investigation period, but in a preliminary survey, treatment with ACE-I was changed to AT-II antagonists in a few cases. One of the reasons for this switch was the appearance of a cough11). Further studies in 
